Swiss pharma giant Roche said it will invest US$50 billion into the US in the next five years to ensure it exports more medicines from the country than it imports, amid threats of potential tariffs on the sector from President Donald Trump.
The Basel-headquartered group said it will expand and upgrade US manufacturing and distribution capabilities for its medicines and diagnostics tests in Kentucky, Indiana, New Jersey, Oregon and California, where it
Other planned investments were flagged, including new manufacturing facilities for gene therapy in Pennsylvania and continuous glucose monitoring in Indiana, with a new manufacturing centre for its weight-loss medicines in a location to be announced.
Roche said it will increase its existing footprint of more than 25,000 employees in 24 sites across eight US states, with the investment expected to create more than 12,000 new jobs.
"Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US," said CEO Thomas Schinecker.